RETRACTED: In silico elucidation of potential drug targets against oxygenase domain of Human eNOS Dysfunction
PLOS ONE · 26.04.2023 · 18 (4) · e0284993
DOI: 10.1371/journal.pone.0284993 ↗Kurz gefasst
Zurückgezogene Publikation in der Zeitschrift PLOS ONE, online erschienen am 26.04.2023. Verfasst von Abbeha Malik und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioinformatics, Institute of Biochemistry, Biotechnology and Bioinformatics, The Islamia University of Bahawalpur, Bahawalpur, Pakistan. Hauptthemen laut MEDLINE: Nitric Oxide Synthase Type III, Calcium. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Nitric Oxide (NO) signaling pathway plays a vital role in various physiological and pathophysiological processes including vasodilation, neurogenesis, inflammation, translation and protein regulation. NO signaling pathway is associated with various diseases such as cardiovascular diseases, vision impairment, hypertension and Alzheimer’s disease. Human Endothelial Nitric Oxide Synthase (eNOS) bound with calcium regulatory protein (calmodulin (CaM)) to produce NO which initiates cGMP pathway. The current study employs to screen the novel compounds against human eNOS independent of calcium regulatory protein (CaM). The current effort emphasized that the deficiency of CaM leads to dysfunction of cGMP signaling pathway. In this work, a hybrid approach of high-throughput virtual screening and comparative molecular docking studies followed by molecular dynamic simulation analyses were applied. The screening of top ranked two novel compounds against eNOS were reported that showed effective binding affinity, retrieved through the DrugBank and ZINC database libraries. Comparative molecular docking analyses revealed that Val-104, Phe-105, Gln-247, Arg-250, Ala-266, Trp-330, Tyr-331, Pro-334, Ala-335, Val-336, Tyr-357, Met-358, Thr-360, Glu-361, Ile-362, Arg-365, Asn-366, Asp-369, Arg-372, Trp-447 and Tyr-475 are potent residues for interactional studies. High-throughput virtual screening approach coupled with molecular dynamic simulation and drug likeness rules depicted that ZINC59677432 and DB00456 are potent compounds to target eNOS. In conclusion, the proposed compounds are potent against eNOS based on extensive in silico analyses. Overall, the findings of this study may be helpful to design therapeutic targets against eNOS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Bioinformatics, Institute of Biochemistry, Biotechnology and Bioinformatics, The Islamia University of Bahawalpur, Bahawalpur, Pakistan.
- Khawaja Muhammad Safdar Medical College Sialkot, Sialkot, Pakistan.
- Faculty of Lifesciences, Department of Zoology, University of Okara, Okara, Pakistan.
- Department of Biotechnology, Institute of Biochemistry, Biotechnology and Bioinformatics, The Islamia University of Bahawalpur, Bahawalpur, Pakistan.
- Department of Biotechnology, University of Okara, Okara, Pakistan.
- Department of Bioinformatics, University of Okara, Okara, Pakistan.
ORCID-Profile: Sheikh Arslan Sehgal
Zitieren
APA
Malik, A., Iqbal, M. N., Ashraf, S., Khan, M. S., Shahzadi, S., Shafique, M. F., Sajid, Z., Sajid, M., & Sehgal, S. A. (2023). RETRACTED: In silico elucidation of potential drug targets against oxygenase domain of Human eNOS Dysfunction. PLOS ONE, 18(4), e0284993. https://doi.org/10.1371/journal.pone.0284993
Vancouver
Malik A, Iqbal MN, Ashraf S, Khan MS, Shahzadi S, Shafique MF, et al. RETRACTED: In silico elucidation of potential drug targets against oxygenase domain of Human eNOS Dysfunction. PLOS ONE. 2023;18(4):e0284993. doi:10.1371/journal.pone.0284993
BibTeX
@article{Malik2023,
author = {Malik, Abbeha and Iqbal, Muhammad Nasir and Ashraf, Sidrah and Khan, Muhammad Saleem and Shahzadi, Samar and Shafique, Muhammad Farhan and Sajid, Zureesha and Sajid, Muhammad and Sehgal, Sheikh Arslan},
title = {RETRACTED: In silico elucidation of potential drug targets against oxygenase domain of Human eNOS Dysfunction},
journal = {PLOS ONE},
year = {2023},
volume = {18},
number = {4},
pages = {e0284993},
doi = {10.1371/journal.pone.0284993}
}
EUVIMED